Synlogic Revenue 2013-2021 | SYBX

Synlogic revenue from 2013 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Synlogic Annual Revenue
(Millions of US $)
2020 $1
2019 $2
2018 $3
2017 $2
2016 $0
2015 $
2014 $
2013 $
2012 $
Synlogic Quarterly Revenue
(Millions of US $)
2021-06-30 $0
2021-03-31
2020-12-31 $0
2020-09-30
2020-06-30 $0
2020-03-31 $0
2019-12-31 $1
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $2
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $2
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.166B $0.001B
Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29